Literature DB >> 28453743

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Cassie N Kline1, Nancy M Joseph2,3, James P Grenert2,3, Jessica van Ziffle2,3, Eric Talevich3, Courtney Onodera3, Mariam Aboian4, Soonmee Cha4,5, David R Raleigh6, Steve Braunstein6, Joseph Torkildson7, David Samuel8, Michelle Bloomer9, Alejandra G de Alba Campomanes9, Anuradha Banerjee1,5, Nicholas Butowski10, Corey Raffel5, Tarik Tihan2, Andrew W Bollen2, Joanna J Phillips2,5, W Michael Korn11, Iwei Yeh2,3, Boris C Bastian2,3, Nalin Gupta5, Sabine Mueller1,5, Arie Perry2,5, Theodore Nicolaides1,5, David A Solomon2,3.   

Abstract

Background: Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neuro-oncology patients.
Methods: We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes.
Results: Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor. In 25 cases (81%), results impacted patient management by: (i) clarifying diagnosis, (ii) identifying pathogenic germline mutations, or (iii) detecting potentially targetable alterations. The pathologic diagnosis was amended after genomic profiling for 6 patients (19%), including a high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to CNS high-grade neuroepithelial tumor with BCOR alteration. Multiple patients had pathogenic germline mutations, many of which were previously unsuspected. Potentially targetable alterations were identified in 19 patients (61%). Additionally, novel likely pathogenic alterations were identified in 3 cases: an in-frame RAF1 fusion in a BRAF wild-type pleomorphic xanthoastrocytoma, an inactivating ASXL1 mutation in a histone H3 wild-type diffuse pontine glioma, and an in-frame deletion within exon 2 of MAP2K1 in a low-grade astrocytic neoplasm. Conclusions: Our experience demonstrates the significant impact of molecular profiling on diagnosis and treatment of pediatric brain tumors and confirms its feasibility for use at the time of diagnosis or recurrence.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  molecular profiling; next-generation sequencing; pediatric brain tumors; personalized therapy; targeted therapeutics

Mesh:

Substances:

Year:  2017        PMID: 28453743      PMCID: PMC5464451          DOI: 10.1093/neuonc/now254

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  23 in total

Review 1.  Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies.

Authors:  Paul A Northcott; Stefan M Pfister; David T W Jones
Journal:  Lancet Oncol       Date:  2015-05-27       Impact factor: 41.316

Review 2.  Medulloblastoma: toward biologically based management.

Authors:  Ayman Samkari; Jason C White; Roger J Packer
Journal:  Semin Pediatr Neurol       Date:  2014-12-24       Impact factor: 1.636

3.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Authors:  Noah A Brown; Larissa V Furtado; Bryan L Betz; Mark J Kiel; Helmut C Weigelin; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-06-30       Impact factor: 22.113

4.  Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.

Authors:  Cassie N Kline; Nancy M Joseph; James P Grenert; Jessica van Ziffle; Iwei Yeh; Boris C Bastian; Sabine Mueller; David A Solomon
Journal:  Neuro Oncol       Date:  2016-02-21       Impact factor: 12.300

5.  Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.

Authors:  Marina N Nikiforova; Abigail I Wald; Melissa A Melan; Somak Roy; Shan Zhong; Ronald L Hamilton; Frank S Lieberman; Jan Drappatz; Nduka M Amankulor; Ian F Pollack; Yuri E Nikiforov; Craig Horbinski
Journal:  Neuro Oncol       Date:  2015-12-17       Impact factor: 12.300

Review 6.  Molecular biology of pediatric brain tumors and impact on novel therapies.

Authors:  Lindsey M Hoffman; Ralph Salloum; Maryam Fouladi
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

7.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

8.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

9.  Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.

Authors:  Ibrahim Qaddoumi; Wilda Orisme; Ji Wen; Teresa Santiago; Kirti Gupta; James D Dalton; Bo Tang; Kelly Haupfear; Chandanamali Punchihewa; John Easton; Heather Mulder; Kristy Boggs; Ying Shao; Michael Rusch; Jared Becksfort; Pankaj Gupta; Shuoguo Wang; Ryan P Lee; Daniel Brat; V Peter Collins; Sonika Dahiya; David George; William Konomos; Kathreena M Kurian; Kathryn McFadden; Luciano Neder Serafini; Hilary Nickols; Arie Perry; Sheila Shurtleff; Amar Gajjar; Fredrick A Boop; Paul D Klimo; Elaine R Mardis; Richard K Wilson; Suzanne J Baker; Jinghui Zhang; Gang Wu; James R Downing; Ruth G Tatevossian; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-01-25       Impact factor: 17.088

10.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Authors:  Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

View more
  97 in total

1.  Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex.

Authors:  Emily Chan; Andrew W Bollen; Deepika Sirohi; Jessica Van Ziffle; James P Grenert; Cassie N Kline; Tarik Tihan; Arie Perry; Nalin Gupta; David A Solomon
Journal:  Acta Neuropathol       Date:  2017-08-03       Impact factor: 17.088

2.  Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.

Authors:  Elke Pfaff; Christian Aichmüller; Martin Sill; Damian Stichel; Matija Snuderl; Matthias A Karajannis; Martin U Schuhmann; Jens Schittenhelm; Martin Hasselblatt; Christian Thomas; Andrey Korshunov; Marina Rhizova; Andrea Wittmann; Anna Kaufhold; Murat Iskar; Petra Ketteler; Dietmar Lohmann; Brent A Orr; David W Ellison; Katja von Hoff; Martin Mynarek; Stefan Rutkowski; Felix Sahm; Andreas von Deimling; Peter Lichter; Marcel Kool; Marc Zapatka; Stefan M Pfister; David T W Jones
Journal:  Acta Neuropathol       Date:  2019-11-25       Impact factor: 17.088

Review 3.  Managing the genomic revolution in cancer diagnostics.

Authors:  Doreen Nguyen; Christopher D Gocke
Journal:  Virchows Arch       Date:  2017-06-21       Impact factor: 4.064

Review 4.  Genomics of adult and pediatric solid tumors.

Authors:  Zahraa Rahal; Farah Abdulhai; Humam Kadara; Raya Saab
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

5.  Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.

Authors:  Armin R Afshar; Melike Pekmezci; Michele M Bloomer; Nicola J Cadenas; Meredith Stevers; Anuradha Banerjee; Ritu Roy; Adam B Olshen; Jessica Van Ziffle; Courtney Onodera; W Patrick Devine; James P Grenert; Boris C Bastian; David A Solomon; Bertil E Damato
Journal:  Ophthalmology       Date:  2019-12-12       Impact factor: 12.079

6.  Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST).

Authors:  Mazen A Atiq; Jessica L Davis; Jason L Hornick; Brendan C Dickson; Christopher D M Fletcher; Jonathan A Fletcher; Andrew L Folpe; Adrián Mariño-Enríquez
Journal:  Mod Pathol       Date:  2020-07-15       Impact factor: 7.842

7.  ALK-positive histiocytosis with KIF5B-ALK fusion in the central nervous system.

Authors:  Calixto-Hope G Lucas; Ahmed Gilani; David A Solomon; Xiayuan Liang; Ossama M Maher; Gabriel Chamyan; Bette K Kleinschmidt-Demasters; Arie Perry
Journal:  Acta Neuropathol       Date:  2019-05-22       Impact factor: 17.088

8.  Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway.

Authors:  Melike Pekmezci; Meredith Stevers; Joanna J Phillips; Jessica Van Ziffle; Boris C Bastian; Nadejda M Tsankova; Bette K Kleinschmidt-DeMasters; Marc K Rosenblum; Tarik Tihan; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2018-02-10       Impact factor: 17.088

9.  High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts.

Authors:  Alexandre Roux; Johan Pallud; Raphaël Saffroy; Myriam Edjlali-Goujon; Marie-Anne Debily; Nathalie Boddaert; Marc Sanson; Stéphanie Puget; Steven Knafo; Clovis Adam; Thierry Faillot; Dominique Cazals-Hatem; Emmanuel Mandonnet; Marc Polivka; Georges Dorfmüller; Aurélie Dauta; Mathilde Desplanques; Albane Gareton; Mélanie Pages; Arnault Tauziede-Espariat; Jacques Grill; Franck Bourdeaut; François Doz; Frédéric Dhermain; Karima Mokhtari; Fabrice Chretien; Dominique Figarella-Branger; Pascale Varlet
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 10.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.